TP53 and ovarian carcinoma: The first dataset involved 10, 389 women receiving neoadjuvant chemotherapy for ovarian cancer, with detailed clinical and demographic data, including ethnicity, ovarian laterality, age at MRI1 (in years), subtype (lymph node-positive, PIK3CA mutation, BRCA mutation, and TP53 mutation), and BMI.